Study record at a glance
| Study ID | NCT04313712 |
|---|---|
| Design | Prospective observational pre-post cohort; all participants were observed before and after ibogaine with magnesium treatment |
| Condition / topic | Blast exposure, head trauma, and PTSD |
| Population | US Special Operations veterans with histories of repeated blast exposure; treatment occurred at an independent clinic in Mexico and Stanford conducted assessments |
| Sample size | 30 participants, actual enrollment |
| Comparator | No randomized or untreated comparator group; one cohort assessed before and after treatment |
| Follow-up | Immediate post-treatment assessment for the registered primary outcome and one-month post-visit assessment for the registered secondary outcome |
| Outcome focus | Change in WHODAS 2.0 disability and functioning scores; the broader editorial record also describes clinical and neuroimaging assessments |
What it suggests
The study provides prospectively collected before-and-after measurements in a defined veteran cohort and a registered framework for examining functioning and disability
What it cannot establish
The observational, uncontrolled design cannot establish causation or comparative efficacy. Selection of a specific veteran population also limits generalization, and the registered record alone does not establish long-term durability
Recruitment relevance
The registry lists this study as completed. It is not a current recruitment opportunity
Do not travel, discontinue medication, or change care based on this summary. The sponsor and the current primary source govern participation decisions.
How this summary was framed
This record reports the design and registered or officially announced research question before interpretation. Unknown sample, comparator, follow-up, and outcome details remain marked as unknown. The Atlas does not infer results from recruitment status, regulatory acceptance, funding, or study completion.